Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes.[6][7][9] It is also used to treat adults with heart failure and chronic kidney disease.[10][11][7] It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.[12]
Dapagliflozin is used along with diet, exercise, and usually with other glucose lowering medications, to improve glycaemic control in adults with type 2 diabetes. Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to existing treatment regimen.[19][20][21][22]
Dapagliflozin is also considered as an option for people with heart failure with reduced ejection fraction with a LVEF <40%.[23] It can be given regardless of current diabetes status, in addition to standard medical therapy. Recent studies have indicated that the use of dapagliflozin and other medications from the SGLT-2 inhibitor class can reduce the risk of worsening heart failure, death, and hospitalization from cardiovascular disease.[23][24] SGLT-2 inhibitors reduce the risk of hospitalisation due to heart failure in people with or without atherosclerotic cardiovascular disease [25][26] A small number of meta-analyses and cohort studies have shown that dapagliflozin is superior to others such as empagliflozin.[27][28][29]
In the European Union, dapagliflozin is indicated in adults:
For the treatment of insufficiently controlled type 2 diabetes as an adjunct to diet and exercise:[7][30][31][32]
in addition to other medicinal products for the treatment of type 2 diabetes;[7]
For the treatment of heart failure with reduced ejection fraction[7]
In November 2021, the European Medicines Agency (EMA) stated that dapagliflozin should no longer be used to treat type 1 diabetes.[9]
Effects in nondiabetic chronic kidney disease
In 2021, the US Food and Drug Administration (FDA) and the EMA expanded the indications for dapagliflozin to include the treatment of people who have chronic kidney disease but don't have diabetes.[33][34] Clinical trials had shown the following effects of such a treatment.
The DIAMOND trial (2017-2019) showed in treatment periods of 6 weeks no improvement of excess proteins in the urine (proteinuria), a significant deterioration of the kidney's filtration rate (reversible within 6 weeks after dapagliflozin discontinuation), and a significant mean loss of body weight of 1.5 kg.[35][36]
The DAPA-CKD trial (2017-2020) showed in a median treatment period of 2.4 years of participants who had already been under ACE or ARB therapy that the events of a sustained decline of 50% in the kidney's filtration rate, kidney failure, or death occurred statistically around eight months later in the treatment group than in the placebo group. In the first 12-16 months of treatment, however, the kidney's filtration rate was worse in the treatment group than in the placebo group, being slightly less negative in the treatment group than in the placebo group only thereafter.[20][36]
Adverse effects
Since dapagliflozin leads to heavy glycosuria (sometimes up to about 70 grams per day), it can lead to rapid weight loss and tiredness. The glucose acts as an osmotic diuretic (this effect is the cause of polyuria in diabetes), which can lead to dehydration. The increased amount of glucose in the urine can also worsen the infections already associated with diabetes, particularly urinary tract infections and thrush (candidiasis). Rarely, use of an SGLT-2 drug, including dapagliflozin, is associated with necrotizing fasciitis of the perineum, also called Fournier gangrene.[37]
Dapagliflozin is also associated with hypotensive reactions. Concerns exist that it may increase the risk of diabetic ketoacidosis.[38] Dapagliflozin and other SGLT2 inhibitors increase the risk of diabetic ketoacidosis in type 2 diabetic patients.[39][40] However, the DEPICT-1 and DEPICT-2 trials showed that dapagliflozin caused additional diabetic ketoacidosis events in the Type I diabetic patients who received dapagliflozin.[41] Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, fatigue, and trouble breathing.[42]
Dapagliflozin can cause dehydration, serious urinary tract infections, and genital yeast infections.[10] Elderly people and people with kidney dysfunction, low blood pressure, or who are on diuretic medications should have their volume status and kidney function assessed.[10] Individuals with signs and symptoms of metabolic acidosis or ketoacidosis should also be assessed.[10] Dapagliflozin can cause low blood sugar when combined with insulin.[10]
To lessen the risk of developing ketoacidosis after surgery, the FDA has approved changes to the prescribing information for SGLT-2 inhibitors to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery.[42]
The glucose lowering effect of dapagliflozin starts to diminish in people with chronic kidney disease with a reduced kidney function (eGFR <45mL/min), and may not be as effective for glycemic control. However, studies have demonstrated a renoprotective effect in reducing kidney function decline, dapagliflozin can still be used to reduce kidney function decline regardless of diabetes status. Therefore, while dapagliflozin can be used in people with diabetes and chronic kidney disease to prevent kidney function decline, further interventions may be needed for glycemic control.[20][43]
Chemistry
The first synthesis of dapagliflozin was disclosed in a patent filed by Bristol Myers Squibb in 2002.[44]
Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.[46] In combination with metformin, dapagliflozin at standard treatment dose of 10 mg daily lowered HbA1c by 0.54-0.84% (5.9-9.3 mmol/mol) when compared to metformin monotherapy in patients with inadequately controlled type 2 diabetes and normal renal function.[47][48][49]
Its protective effects in heart failure is attributed primarily to haemodynamic effects, where SGLT2 inhibitors potently reduce intravascular volume through osmotic diuresis and natriuresis. This consequently may lead to a reduction in preload and afterload, thereby alleviating cardiac workload and improving left ventricular function.[50]
Selectivity
The IC50 for SGLT2 is less than one-thousandth of the IC50 for SGLT1 (1.1 versus 1390 nmol/L), so that the drug does not interfere with intestinal glucose absorption.[51]
In July 2016, the fixed-dose combination of saxagliptin and dapagliflozin was approved for medical use in the European Union and is sold under the brand name Qtern.[57] The combination drug was approved for medical use in the United States in February 2017, where it also is sold under the brand name Qtern.[58][59]
In May 2019, the fixed-dose combination of dapagliflozin, saxagliptin, and metformin hydrochloride as extended-release tablets was approved in the United States to improve glycemic control in adults with type 2 diabetes when used in combination with diet and exercise. The FDA granted the approval of Qternmet XR to AstraZeneca.[60] The combination drug was approved for use in the European Union in November 2019, and is sold under the brand name Qtrilmet.[61]
Dapagliflozin was found effective in several studies in participants with type 2.[7] The main measure of effectiveness was the level of glycated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.[7]
In two studies involving 840 participants with type 2 diabetes, dapagliflozin when used alone decreased HbA1c levels by 0.66% more than placebo (a dummy treatment) after 24 weeks.[7] In four other studies involving 2,370 participants, adding dapagliflozin to other diabetes medicines decreased HbA1c levels by 0.54–0.68% more than adding placebo after 24 weeks.[7]
In a study involving 814 participants with type 2 diabetes, dapagliflozin used in combination with metformin was at least as effective as a sulphonylurea (another type of diabetes medicines) used with metformin.[7] Both combinations reduced HbA1c levels by 0.52% after 52 weeks.[7]
A long-term study, involving over 17,000 participants with type 2 diabetes, looked at the effects of dapagliflozin on cardiovascular (heart and circulation) disease.[7] The study indicated that dapagliflozin's effects were in line with those of other diabetes medicines that also work by blocking SGLT2.[7]
In two studies involving 1,648 participants with type 1 diabetes whose blood sugar was not controlled well enough on insulin alone, adding dapagliflozin 5 mg decreased HbA1c levels after 24 hours by 0.37% and by 0.42% more than adding placebo.[7]
Dapagliflozin was approved for medical use in the European Union in November 2012.[7] It is marketed in a number of European countries.[62]
Dapagliflozin was approved for medical use in the United States in January 2014.[63][33]
In 2020, the US FDA expanded the indications for dapagliflozin to include treatment for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.[10] It is the first in this particular drug class, sodium-glucose co-transporter 2 inhibitors, to be approved to treat adults with New York Heart Association's functional class II-IV heart failure with reduced ejection fraction.[10]
The results of the DAPA-HF and DECLARE-TIMI 58 clinical trials demonstrated the efficacy of dapagliflozin compared to placebo in improving survival in adults with heart failure with reduced ejection fraction by 17%. They both showed a reduction in the number of hospitalizations from worsening heart failure, cardiovascular death and all-cause mortality.[23][64]
The safety and effectiveness of dapagliflozin were evaluated in a randomized, double-blind, placebo-controlled study of 4,744 participants.[10] The average age of participants was 66 years and more participants were male (77%) than female.[10] To determine the drug's effectiveness, investigators examined the occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart-failure visits.[10] Participants were randomly assigned to receive a once-daily dose of either 10 mg of dapagliflozin or a placebo (inactive treatment).[10] After about 18 months, people who received dapagliflozin had fewer cardiovascular deaths, hospitalizations for heart failure, and urgent heart-failure visits than those receiving the placebo.[10]
In July 2020, the FDA granted AstraZeneca a Fast Track Designation in the US for the development of dapagliflozin to reduce the risk of hospitalization for heart failure or cardiovascular death in adults following a heart attack.[65]
In August 2020, detailed results from the Phase III DAPA-CKD trial reportedly showed that dapagliflozin on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease stages 2–4 and elevated urinary albumin excretion. The results were consistent in patients both with and without type 2 diabetes.[66]
In April 2021, the FDA expanded the indications for dapagliflozin to include reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression.[33] The efficacy of dapagliflozin to improve kidney outcomes and reduce cardiovascular death in people with chronic kidney disease was evaluated in a multicenter, double-blind study of 4,304 participants.[33]
In February 2023, the EU approved dapagliflozin for extended use to cover heart failure patients across the full spectrum of left ventricular ejection fraction (LVEF), including those with mildly reduced and preserved ejection fraction.[67][68]
Society and culture
Legal status
A generic version of dapagliflozin was approved by the US FDA in February 2022,[69] but cannot be sold until October 2025.[70][71] A generic version was approved in Canada in May 2023.[72]
In January 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for a generic version of Forxiga, which has been authorized in the EU since November 2012.[73] Dapagliflozin Viatris was approved for medical used in the European Union in March 2023.[8]
Research
A systematic review concluded that dapagliflozin reduced heart failure hospitalization, cardiovascular death, and all-cause mortality in people with HFrEF (i.e., congestive heart failure) and diabetes.[74]
^ abc"Farxiga- dapagliflozin tablet, film coated". DailyMed. National Institutes of Health, National Library of Medicine, U.S. Department of Health & Human Services. 3 February 2020. Archived from the original on 30 October 2020. Retrieved 5 May 2020.
^ abcdefghijklmnopqr"Forxiga EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 17 February 2020. Retrieved 17 February 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ ab"Dapagliflozin Viatris EPAR". European Medicines Agency. 4 April 2023. Retrieved 17 June 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF (October 2014). "Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events". Drug Safety. 37 (10): 815–829. doi:10.1007/s40264-014-0213-4. PMID25096959. S2CID24064402.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. (June 2019). "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy". The New England Journal of Medicine. 380 (24): 2295–2306. doi:10.1056/NEJMoa1811744. hdl:1805/22369. PMID30990260. S2CID117730201.
^Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. (January 2019). "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials". Lancet. 393 (10166): 31–39. doi:10.1016/S0140-6736(18)32590-X. PMID30424892. S2CID53277899.
^"Forxiga EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 17 February 2020. Retrieved 17 February 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes". New England Journal of Medicine. 380 (19): 1880–1882. 9 May 2019. doi:10.1056/NEJMc1902837. ISSN0028-4793.
^Liu J, Li L, Li S, Wang Y, Qin X, Deng K, et al. (September 2020). "Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials". Diabetes, Obesity & Metabolism. 22 (9): 1619–1627. doi:10.1111/dom.14075. PMID32364674.
^US patent 6515117B2, Ellsworth B, Washburn WN, Sher PM, Wu G, Meng W, "C-aryl glucoside SGLT2 inhibitors and method", published 2003-02-04, assigned to AstraZeneca
^Sagandira CR, Khasipo AZ, Sagandira MB, Watts P (2021). "An overview of the synthetic routes to essential oral anti-diabetes drugs". Tetrahedron. 96: 132378. doi:10.1016/j.tet.2021.132378.
^Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (June 2010). "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial". Lancet. 375 (9733): 2223–2233. doi:10.1016/S0140-6736(10)60407-2. PMID20609968. S2CID9168659.
^"Dapagliflozin Viatris: Pending EC decision". European Medicines Agency. 26 January 2023. Archived from the original on 27 January 2023. Retrieved 29 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Artikel ini perlu diwikifikasi agar memenuhi standar kualitas Wikipedia. Anda dapat memberikan bantuan berupa penambahan pranala dalam, atau dengan merapikan tata letak dari artikel ini. Untuk keterangan lebih lanjut, klik [tampil] di bagian kanan. Mengganti markah HTML dengan markah wiki bila dimungkinkan. Tambahkan pranala wiki. Bila dirasa perlu, buatlah pautan ke artikel wiki lainnya dengan cara menambahkan [[ dan ]] pada kata yang bersangkutan (lihat WP:LINK untuk keterangan lebih lanjut). …
Ketua Majelis Permusyawaratan Rakyat Republik IndonesiaPetahanaBambang Soesatyosejak 3 Oktober 2019Masa jabatan5 tahunDibentuk1960Pejabat pertamaChaerul SalehSitus webhttps://www.mpr.go.id/ Ketua Majelis Permusyawaratan Rakyat Republik Indonesia adalah salah satu dari lima pimpinan Majelis Permusyawaratan Rakyat (MPR) yang dipilih dari dan oleh anggota MPR.[1] Pimpinan MPR bertugas: memimpin sidang MPR dan menyimpulkan hasil sidang untuk diambil keputusan; menyusun rencana kerja dan…
artikel berbunyi seperti sebuah rilis pers atau artikel berita dan tergantung pada liputan jurnalistik rutin atau sensasionalisme. Harap mengembangkan artikel ini dengan sumber yang tepercaya dan patut untuk memenuhi pedoman gaya Wikipedia. Artikel ini membutuhkan rujukan tambahan agar kualitasnya dapat dipastikan. Mohon bantu kami mengembangkan artikel ini dengan cara menambahkan rujukan ke sumber tepercaya. Pernyataan tak bersumber bisa saja dipertentangkan dan dihapus.Cari sumber: Jalan …
اتحاد منغوليا لكرة القدم الاسم المختصر MFF الرياضة كرة القدم أسس عام 1959 الرئيس رينتشينيام امارجارغال الانتسابات الفيفا : 1998 AFC : 1998 رمز الفيفا MNG الموقع الرسمي www.the-mff.mn تعديل مصدري - تعديل تأسس الاتحاد المنغولي لكرة القدم في عام 1959م وانضم إلى الاتحاد الدولي لكرة الق…
Election for mayor of Durham, North Carolina 2023 Durham mayoral election ← 2021 November 7, 2023 2025 → Candidate Leonardo Williams Mike Woodard Popular vote 24,124 13,755 Percentage 63.5% 36.2% County results Precinct results[a] City council ward resultsWilliams: 50–60% 60–70% 70–80% 80–90% ≥90%…
Disambiguazione – Se stai cercando altri significati, vedi Serie C 1946-1947 (disambigua). Serie C 1946-1947 Competizione Serie C Sport Calcio Edizione 9ª Organizzatore FIGC Luogo Italia Partecipanti 143 squadre (Nord)83 squadre (Centro)40 squadre (Sud) Formula 9 gironi+3 gironi finali (Nord)6 gironi+girone finale (Centro)3 gironi+girone finale (Sud) Risultati Promozioni MagentaVita NovaBolzanoCenteseGubbioNocerina Retrocessioni (le squadre scritte in corsivo sono poi state riammesse) F…
Disambiguazione – Se stai cercando altri significati, vedi Canal (disambigua). Canal D'azzurro al palo accostato da sei gigli, tre per parte, il tutto di oro[1] D'argento, allo scaglione d'azzurro[2] Stato Repubblica di Venezia TitoliPatrizi veneti EtniaItaliana Manuale I Canal (o da Canal) furono una famiglia patrizia veneziana. Pur essendo stati inclusi nella serrata del Maggior Consiglio del 1297[3][4][5], erano considerati di nobiltà più …
Padmini KolhapureKolhapure pada April 2017Lahir1 November 1965 (umur 58)Mumbai, Maharashtra, IndiaPekerjaanAktris, penyanyiSuami/istriPradeep Sharma (1986)AnakPriyank Pradeep SharmaPenghargaan Penghargaan Filmfare untuk Aktris Pendukung Terbaik Penghargaan Filmfare untuk Aktris Terbaik Padmini Kolhapure (kelahiran 1 November 1965) adalah seorang aktris dan penyanyi asal India, yang berkarya di perfilman Hindi. Ia memulai akting pada 1972 pada usia 7, dan karya-karya terawalnya meliputi Zind…
Voce principale: Unione Sportiva Lecce. Unione Sportiva LecceStagione 2000-2001Sport calcio Squadra Lecce Allenatore Alberto Cavasin Presidente Mario Moroni Serie A13º posto Coppa ItaliaOttavi di finale Maggiori presenzeCampionato: Vugrinec, Chimenti (34) Miglior marcatoreCampionato: Lucarelli (12)Totale: Lucarelli, Vugrinec (14) 1999-2000 2001-2002 Si invita a seguire il modello di voce Questa voce raccoglie le informazioni riguardanti l'Unione Sportiva Lecce nelle competizioni ufficiali …
1983 drama film directed by James L. Brooks This article is about the film. For other uses, see Terms of Endearment (disambiguation). Terms of EndearmentTheatrical release posterDirected byJames L. BrooksScreenplay byJames L. BrooksBased onTerms of Endearmentby Larry McMurtryProduced byJames L. BrooksStarring Debra Winger Shirley MacLaine Jack Nicholson Danny DeVito John Lithgow CinematographyAndrzej BartkowiakEdited byRichard MarksMusic byMichael GoreDistributed byParamount PicturesRelease date…
Questa voce sull'argomento cestisti statunitensi è solo un abbozzo. Contribuisci a migliorarla secondo le convenzioni di Wikipedia. Segui i suggerimenti del progetto di riferimento. Runt Pullins Nazionalità Stati Uniti d'America Altezza 173[1] cm Pallacanestro Ruolo Ala[2] Termine carriera 1958 Hall of fame Naismith Hall of Fame (2022) CarrieraGiovanili Wendell Phillips High SchoolSquadre di club 1929-1934 Harlem Globetrotters1934-1958Harlem Clowns Il simbo…
ХристианствоБиблия Ветхий Завет Новый Завет Евангелие Десять заповедей Нагорная проповедь Апокрифы Бог, Троица Бог Отец Иисус Христос Святой Дух История христианства Апостолы Хронология христианства Раннее христианство Гностическое христианство Вселенские соборы Ни…
Oesterreichische NationalbankKantor pusatWinaDidirikan1 Juni 1816; 207 tahun lalu (1816-06-01)Pemilik100% kepemilikan negara[1]GubernurRobert HolzmannNegaraAustriaMata uangEuroEUR (ISO 4217)Cadangan9 620 juta USD[1]PendahuluOesterreichisch-ungarische BankPenggantiEuropean Central Bank (1999)1Situs weboenb.at1 Oesterreichische Nationalbank masih ada tetapi banyak fungsi telah diambil alih oleh ECB. Oesterreichische Nationalbank (OeNB) adalah bank sentral Austria dan, den…